Ropes & Gray Advises Innovent Biologics in Collaboration with Eli Lilly
The global law firm Ropes & Gray advised Innovent Biologics, Inc., a leading biopharmaceutical company in China, in a collaboration with Eli Lilly and Company, a global healthcare leader.
The two companies described their agreement, first announced on March 20, as one of the largest biotech drug collaborations in China between a multi-national and domestic company. Eli Lilly and Innovent said they will collaborate to support the development and potential commercialization of at least three cancer treatments over the next decade.
Michael Yu, Ph.D., co-founder, president and CEO of Innovent, stated in a joint press release issued by the two companies: “This groundbreaking collaboration establishes Innovent as the very first company in China to form such a broad alliance with a global pharmaceutical company, and we are honored to collaborate with a company as esteemed as Lilly. Given our experience, significant insights into the China market and international compliance standards, we strongly believe Innovent is ideally suited to serve as Lilly's Chinese collaborator of choice.”
Ropes & Gray attorneys advised Innovent, which is focused on the development and manufacturing of complex, high-end biologics for both the Asian and global markets that meet EMA and FDA/cGMP standards, on the collaboration agreement. The Ropes & Gray team was led by Shanghai-based partner Geoffrey Lin (intellectual property).
Ropes & Gray is a global law firm with more than 1,100 lawyers located in 11 offices, including Shanghai, Hong Kong, Seoul, Tokyo, London, New York, Boston, Washington, D.C., Chicago, San Francisco and Silicon Valley. The firm’s internationally recognized China life sciences practice offers integrated and comprehensive counsel to leading investment funds and global pharmaceutical, medical device and biotechnology companies on doing business in one of the world’s fastest growing markets. Ropes & Gray provides a cross-practice team with market-leading corporate/M&A, intellectual property, regulatory and compliance practitioners, all of whom are based on the ground in China.
Read more about the collaboration in the companies’ press release here.